Multiple Sclerosis – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sat, 29 Jul 2023 17:14:53 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Multiple Sclerosis – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Low Doses of β-Caryophyllene Reduced Clinical and Paraclinical Parameters of an Autoimmune Animal Model of Multiple Sclerosis: Investigating the Role of CB2 Receptors in Inflammation by Lymphocytes and Microglial https://www.cannabisclinicians.org/2023/07/29/low-doses-of-%ce%b2-caryophyllene-reduced-clinical-and-paraclinical-parameters-of-an-autoimmune-animal-model-of-multiple-sclerosis-investigating-the-role-of-cb2-receptors-in-inflammation-by-lymphocyt/ Sat, 29 Jul 2023 17:14:53 +0000 https://www.cannabisclinicians.org/?p=28986 Multiple Sclerosis (MS) is a prevalent inflammatory disease in which the immune system plays an essential role in the damage, inflammation, and demyelination of central nervous system neurons (CNS). The cannabinoid receptor type 2 (CB2) agonists possess anti-inflammatory effects against noxious stimuli and elevate the neuronal survival rate. We attempted to analyze the protective impact of low doses of β-Caryophyllene (BCP) in experimental autoimmune encephalomyelitis (EAE) mice as a chronic MS model. Immunization of female C57BL/6 mice was achieved through two subcutaneous injections into different areas of the hind flank with an emulsion that consisted of myelin Myelin oligodendrocyte glycoprotein (MOG)35–55 (150 µg) and complete Freund’s adjuvant (CFA) (400 µg) with an equal volume. Two intraperitoneal (i.p.) injections of pertussis toxin (300 ng) were performed on the animals on day zero (immunizations day) and 48 h (2nd day) after injection of MOG + CFA. The defensive effect of low doses of BCP (2.5 and 5 mg/kg/d) was investigated in the presence and absence of a CB2 receptor antagonist (1 mg/kg, AM630) in the EAE model. We also examined the pro/anti-inflammatory cytokine levels and the polarization of brain microglia and spleen lymphocytes in EAE animals. According to our findings, low doses of BCP offered protective impacts in the EAE mice treatment in a CB2 receptor-dependent way. In addition, according to results, BCP decreased the pathological and clinical defects in EAE mice via modulating adaptive (lymphocytes) and innate (microglia) immune systems from inflammatory phenotypes (M1/Th1/Th17) to anti-inflammatory (M2/Th2/Treg) phenotypes. Additionally, BCP elevated the anti-inflammatory cytokine IL-10 and reduced blood inflammatory cytokines. BCP almost targeted the systemic immune system more than the CNS immune system. Thus, a low dose of BCP can be suggested as a therapeutic effect on MS treatment with potent anti-inflammatory effects and possibly lower toxicity.

The post Low Doses of β-Caryophyllene Reduced Clinical and Paraclinical Parameters of an Autoimmune Animal Model of Multiple Sclerosis: Investigating the Role of CB2 Receptors in Inflammation by Lymphocytes and Microglial appeared first on Society of Cannabis Clinicians.

]]> Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population https://www.cannabisclinicians.org/2023/06/03/multiple-sclerosis-and-use-of-medical-cannabis-a-retrospective-review-of-a-neurology-outpatient-population-2/ Sat, 03 Jun 2023 19:35:49 +0000 https://www.cannabisclinicians.org/?p=28749 Patients diagnosed as having multiple sclerosis (MS) experience a wide range of symptoms requiring pharmacologic management, and many do not achieve adequate symptom control. The purpose of this study was to evaluate the role of medical cannabis (MC) as part of a comprehensive treatment plan for patients with MS. A retrospective medical record review of 141 patients with MS receiving MC for symptom management was conducted. Data were collected for up to 4 follow-up appointments after initiation of MC. Outcomes included changes in MS symptoms, medication changes, adverse events, and changes in cognition and mobility.

The post Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population appeared first on Society of Cannabis Clinicians.

]]> A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington https://www.cannabisclinicians.org/2021/08/25/a-cross-sectional-survey-of-cannabis-use-by-people-with-ms-in-oregon-and-southwest-washington/ Wed, 25 Aug 2021 14:51:09 +0000 https://www.cannabisclinicians.org/?p=24065 Evidence supports that cannabinoids reduce self-reported spasticity and neuropathic pain in people with MS (PwMS), and legal access to cannabis for medical and recreational use continues to rise. However, there are limited data regarding patterns of cannabis use and perceived benefits of cannabis among PwMS in the US. This study describes the prevalence of cannabis use, routes of administration, perceived benefit of cannabis for MS, and characteristics associated with cannabis use and perception of benefit among a population of PwMS living in two states where cannabis is legal for both medical and recreational use.

The post A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington appeared first on Society of Cannabis Clinicians.

]]> Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases https://www.cannabisclinicians.org/2021/06/03/therapeutic-prospects-of-cannabinoids-in-the-immunomodulation-of-prevalent-autoimmune-diseases/ Thu, 03 Jun 2021 19:07:57 +0000 https://www.cannabisclinicians.org/?p=23209 Cannabinoids such as ▵-9-THC and CBD can downregulate the immune response by modulating the endocannabinoid system. This modulation is relevant for the treatment of prevalent autoimmune diseases (ADs), such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), diabetes mellitus type 1 (DMT1), and rheumatoid arthritis (RA). These conditions require new therapeutic options with fewer side effects for the control of the autoimmune response. Objective: to conduct a literature review of preclinical scientific evidence that supports further clinical investigations for the use of cannabinoids (natural or synthetic) as potential immunomodulators of the immune response in ADs.

The post Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases appeared first on Society of Cannabis Clinicians.

]]> Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence https://www.cannabisclinicians.org/2021/05/27/cannabis-a-miracle-drug-with-polyvalent-therapeutic-utility-preclinical-and-clinical-based-evidence/ Thu, 27 May 2021 21:48:54 +0000 https://www.cannabisclinicians.org/?p=23137 Cannabis sativa L. is an annual herbaceous dioecious plant which was first cultivated by agricultural human societies in Asia. Over the period of time, various parts of the plant like leaf, flower, and seed were used for recreational as well as therapeutic purposes. The main chemical components of Cannabis sativa are termed as cannabinoids, among them the key psychoactive constituent is Δ-9-tetrahydrocannabinol and cannabidiol (CBD) as active nonpsychotic constituent. Upon doing extensive literature review, it was found that cannabis has been widely studied for a number of disorders. Very recently, a pure CBD formulation, named Epidiolex, got a green flag from both United States Food and Drug Administration and Drug Enforcement Administration for 2 rare types of epilepsies. This laid a milestone in medical cannabis research. This review intends to give a basic and extensive assessment, from past till present, of the ethnological, plant, chemical, pharmacological, and legal aspects of C. sativa.

The post Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence appeared first on Society of Cannabis Clinicians.

]]> Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review https://www.cannabisclinicians.org/2021/02/01/immunomodulatory-potential-of-cannabidiol-in-multiple-sclerosis-a-systematic-review/ Mon, 01 Feb 2021 16:17:49 +0000 https://www.cannabisclinicians.org/?p=21357 Authors Alessia Furgiuele, Marco Cosentino, Marco Ferrari & Franca Marino Published in Journal of Neuroimmune Pharmacology January 2021 Abstract Multiple sclerosis (MS) is the most common chronic autoimmune disease of...

The post Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review appeared first on Society of Cannabis Clinicians.

]]> Cannabis Therapeutics and the Future of Neurology https://www.cannabisclinicians.org/2020/08/17/cannabis-therapeutics-and-the-future-of-neurology/ Mon, 17 Aug 2020 15:56:53 +0000 https://www.cannabisclinicians.org/?p=19234 Author: Ethan B. Russo Published in: Frontiers in Integrative Neuroscience  October 2018 Abstract Introduction: Cannabis burst across the Western medicine horizon after its introduction by William O’Shaughnessy in 1838 (O’Shaughnessy, 1838–1840;...

The post Cannabis Therapeutics and the Future of Neurology appeared first on Society of Cannabis Clinicians.

]]> Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders https://www.cannabisclinicians.org/2020/07/17/pharmacokinetics-of-sativex-in-dogs-towards-a-potential-cannabinoid-based-therapy-for-canine-disorders/ Fri, 17 Jul 2020 22:31:40 +0000 https://www.cannabisclinicians.org/?p=18836 Authors: María Fernández-Trapero, Carmen Pérez-Díaz, Francisco Espejo-Porras, Eva de Lago, Javier Fernández-Ruiz Published in Biomolecules February 2020 Abstract The phytocannabinoid-based medicine Sativex® is currently marketed for the treatment of spasticity and...

The post Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol for Viral Diseases: Hype or Hope? https://www.cannabisclinicians.org/2020/07/15/cannabidiol-for-viral-diseases-hype-or-hope/ Wed, 15 Jul 2020 20:57:49 +0000 https://www.cannabisclinicians.org/?p=18820 Authors: Alex Mabou Tagne, Barbara Pacchetti, Mikael Sodergren, Marco Cosentino, and Franca Marino Published in Mary Ann Liebert, Inc Publishers June 2020 Abstract Background: The possibility of cannabidiol (CBD) to be...

The post Cannabidiol for Viral Diseases: Hype or Hope? appeared first on Society of Cannabis Clinicians.

]]> Efficacy of cannabidiol treatment in experimental MS is due to immunosuppressive activity of myeloid cells in CNS downregulating recruitment of CD4+ T cells, proinflammatory chemokines and gasdermin D expression https://www.cannabisclinicians.org/2020/06/15/cbd-for-multiple-sclerosis-immunosupressive-2/ Mon, 15 Jun 2020 11:54:17 +0000 https://www.cannabisclinicians.org/?p=18521 Authors: Nicholas Dopkins, Kiesha Wilson, Kathryn Miranda, Prakash S Nagarkatti and Mitzi Nagarkatti Published in The Journal of Immunology May 2020   Abstract Cannabidiol (CBD) is a nonpsychoactive ingredient from...

The post Efficacy of cannabidiol treatment in experimental MS is due to immunosuppressive activity of myeloid cells in CNS downregulating recruitment of CD4+ T cells, proinflammatory chemokines and gasdermin D expression appeared first on Society of Cannabis Clinicians.

]]>